Exact Sciences (NASDAQ: EXAS) modeling shows 5.5x more advanced lesions with mt‑sDNA

5 days ago 5

ACG 2025 data show 53.4% completion in mt‑sDNA users and 129% higher testing after digital outreach; modeling estimates 2% total and 3% treatment cost reductions.

1. Homepage
2. Colon Cancer
3. Exact Sciences (NASDAQ: EXAS) modeling shows 5.5x more advanced lesions with mt‑sDNA